PharmacoEconomics - open

Keyphrases

Publications

volume 8, number 4, 2024

Gérard de Pouvourville, Manon Breau-Brunel, Véronique Loncle-Provot, Ekkehard C Beck, Loïg Gaugain, Gaëlle Nachbaur, Celine Pribil
Public Health Impact and Cost-Effectiveness Analysis of 4-Component Meningococcal Serotype B Vaccination for Infants in France. PharmacoEconomics - open 8 (4) (2024)
Carlos Rojas-Roque, Constanza Silvestrini, Fernando J Argento, Daniela Sugg, Federico Augustovski, Jesica Coelli, Natalia Espinola
Budget Impact Analysis of Olaparib in Combination with Bevacizumab for Maintenance Therapy for Ovarian Cancer in Argentina. PharmacoEconomics - open 8 (4) (2024)
Najmeh Moradi, Leila Zarei, Narges Hajimoladarvish, Zahra Meshkani, Marzieh Zanganeh, Jafar Babapour, Kamran Bagheri Lankarani
Public Preference for Financing Preventive Vaccines in Health Shocks: The Case of COVID-19 Vaccines in a Middle-Income Country. PharmacoEconomics - open 8 (4) (2024)
Rachael Maree Hunter, Matthew Franklin
Whither Decision-Analytic Modelling-Based Economic Evaluation for Health Care Decision Making? PharmacoEconomics - open 8 (4) (2024)
Micha J Pilz, Simone Seyringer, Imad Al-Naesan, Madeleine T King, Andrew Bottomley, Richard Norman, Lisa Schlosser, Tobias Hell, Eva Maria Gamper, null null
Cancer-Specific Health Utilities: Evaluation of Core Measurement Properties of the EORTC QLU-C10D in Lung Cancer Patients-Data from Four Multicentre LUX-Lung Trials, Applying Six Country Tariffs. PharmacoEconomics - open 8 (4) (2024)
Emma McManus
Evaluating the Long-Term Cost-Effectiveness of the English NHS Diabetes Prevention Programme using a Markov Model. PharmacoEconomics - open 8 (4) (2024)
Colin Burke, Catriona Crossan, Emma Tyas, Matthew Hemstock, Dawn Lee, Sally Bowditch
A Cost-Utility Analysis of Add-On Cannabidiol Versus Usual Care Alone for the Treatment of Seizures Associated with Tuberous Sclerosis Complex in England and Wales. PharmacoEconomics - open 8 (4) (2024)
Sudewi Mukaromah Khoirunnisa, Fithria Dyah Ayu Suryanegara, Lisa Aniek de Jong, Didik Setiawan, Maarten Jacobus Postma
A Systematic Review of Health-Related Quality of Life in Women with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab. PharmacoEconomics - open 8 (4) (2024)
Rodney S Taylor, Anthony Bentley, Kaylie Metcalfe, Melvin D Lobo, Ajay J Kirtane, Michel Azizi, Christopher Clark, Kieran Murphy, Jennifer H Boer, Marjolijn van Keep, An Thu Ta, Neil C Barman, Garrett Schwab, Ron Akehurst, Roland E Schmieder
Cost Effectiveness of Endovascular Ultrasound Renal Denervation in Patients with Resistant Hypertension. PharmacoEconomics - open 8 (4) (2024)
Gérard de Pouvourville, Manon Breau-Brunel, Véronique Loncle-Provot, Ekkehard C Beck, Loïg Gaugain, Gaëlle Nachbaur, Celine Pribil
Public Health Impact and Cost-Effectiveness Analysis of 4-Component Meningococcal Serotype B Vaccination for Infants in France. PharmacoEconomics - open 8 (4) (2024)
Samir Garg, Narayan Tripathi, Kirtti Kumar Bebarta
Cost of Care for Non-communicable Diseases: Which Types of Healthcare Providers are the Most Economical in India's Chhattisgarh State? PharmacoEconomics - open 8 (4) (2024)
Carlos Rojas-Roque, Constanza Silvestrini, Fernando J Argento, Daniela Sugg, Federico Augustovski, Jesica Coelli, Natalia Espinola
Budget Impact Analysis of Olaparib in Combination with Bevacizumab for Maintenance Therapy for Ovarian Cancer in Argentina. PharmacoEconomics - open 8 (4) (2024)
Najmeh Moradi, Leila Zarei, Narges Hajimoladarvish, Zahra Meshkani, Marzieh Zanganeh, Jafar Babapour, Kamran Bagheri Lankarani
Public Preference for Financing Preventive Vaccines in Health Shocks: The Case of COVID-19 Vaccines in a Middle-Income Country. PharmacoEconomics - open 8 (4) (2024)
Sudewi Mukaromah Khoirunnisa, Fithria Dyah Ayu Suryanegara, Lisa Aniek de Jong, Didik Setiawan, Maarten Jacobus Postma
A Systematic Review of Health-Related Quality of Life in Women with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab. PharmacoEconomics - open 8 (4) (2024)

volume 8, number 5, 2024

Jonathan Salcedo, Daniel Hill-McManus, Chloë Hardern, Oyin Opeifa, Raffaella Viti, Ludovica Siviero, Antonio Saverio Roscini, Gennaro Di Martino
Cost-Effectiveness of Vedolizumab as a First-Line Advanced Therapy Versus Adalimumab Treatment Sequences for Ulcerative Colitis in Italy. PharmacoEconomics - open 8 (5) (2024)
Vittoria Ardito, Ludovico Cavallaro, Michael F Drummond, Oriana Ciani
Mapping Payment and Pricing Schemes for Health Innovation: Protocol of a Scoping Literature Review. PharmacoEconomics - open 8 (5) (2024)
Sonila M Tomini, Efthalia Massou, Nadia E Crellin, Naomi J Fulop, Theo Georghiou, Lauren Herlitz, Ian Litchfield, Pei Li Ng, Christopher Sherlaw-Johnson, Manbinder S Sidhu, Holly Walton, Stephen Morris
A Cost Evaluation of COVID-19 Remote Home Monitoring Services in England. PharmacoEconomics - open 8 (5) (2024)
Richard St John Nicholas, Erik Scalfaro, Rachel Dorsey, Zuzanna Angehrn, Judit Banhazi, Roisin Brennan, Nicholas Adlard
ENTIMOS: Decision Support Tool Highlights Potential Impact of Non-intravenous Therapies for Multiple Sclerosis on Patient Care via Clinical Scenario Simulation. PharmacoEconomics - open 8 (5) (2024)
Vittoria Ardito, Ludovico Cavallaro, Michael F Drummond, Oriana Ciani
Mapping Payment and Pricing Schemes for Health Innovation: Protocol of a Scoping Literature Review. PharmacoEconomics - open 8 (5) (2024)
Jürgen Wasem, Yanic Heer, Eleni Karamasioti, Erwan Muros-Le Rouzic, Giuseppe Marcelli, Danilo Di Maio, Stefan Braune, Gisela Kobelt, Paul Dillon
Cost and Quality of Life of Disability Progression in Multiple Sclerosis Beyond EDSS: Impact of Cognition, Fatigue, and Limb Impairment. PharmacoEconomics - open 8 (5) (2024)
Dawn Lee, Darren Burns, Ed Wilson
NICE's Pathways Pilot: Pursuing Good Decision Making in Difficult Circumstances. PharmacoEconomics - open 8 (5) (2024)
Jürgen Wasem, Yanic Heer, Eleni Karamasioti, Erwan Muros-Le Rouzic, Giuseppe Marcelli, Danilo Di Maio, Stefan Braune, Gisela Kobelt, Paul Dillon
Cost and Quality of Life of Disability Progression in Multiple Sclerosis Beyond EDSS: Impact of Cognition, Fatigue, and Limb Impairment. PharmacoEconomics - open 8 (5) (2024)
Jürgen Wasem, Yanic Heer, Eleni Karamasioti, Erwan Muros-Le Rouzic, Giuseppe Marcelli, Danilo Di Maio, Stefan Braune, Gisela Kobelt, Paul Dillon
Cost and Quality of Life of Disability Progression in Multiple Sclerosis Beyond EDSS: Impact of Cognition, Fatigue, and Limb Impairment. PharmacoEconomics - open 8 (5) (2024)
Diana Beatriz S Bayani, Yihao Clement Lin, Chandramouli Nagarajan, Melissa Gaik-Ming Ooi, Allison Ching Yee Tso, John Cairns, Hwee Lin Wee
Modeling First-Line Daratumumab Use for Newly Diagnosed, Transplant-Ineligible, Multiple Myeloma: A Cost-Effectiveness and Risk Analysis for Healthcare Payers. PharmacoEconomics - open 8 (5) (2024)
Dawn Lee, Darren Burns, Ed Wilson
NICE's Pathways Pilot: Pursuing Good Decision Making in Difficult Circumstances. PharmacoEconomics - open 8 (5) (2024)
Richard St John Nicholas, Erik Scalfaro, Rachel Dorsey, Zuzanna Angehrn, Judit Banhazi, Roisin Brennan, Nicholas Adlard
ENTIMOS: Decision Support Tool Highlights Potential Impact of Non-intravenous Therapies for Multiple Sclerosis on Patient Care via Clinical Scenario Simulation. PharmacoEconomics - open 8 (5) (2024)
She Hui Tan, Louise Gek Huang Goh, Benjamin Shao Kiat Ong, Darren Sze Guan Ng, Liang Lin, Raymond Chee Hui Ng, Bernard Yu-Hor Thong, Kwong Ng
Impact of Value-Driven Healthcare Strategies for Biosimilar Adoption: The Singapore Story. PharmacoEconomics - open 8 (5) (2024)
Sonila M Tomini, Efthalia Massou, Nadia E Crellin, Naomi J Fulop, Theo Georghiou, Lauren Herlitz, Ian Litchfield, Pei Li Ng, Christopher Sherlaw-Johnson, Manbinder S Sidhu, Holly Walton, Stephen Morris
A Cost Evaluation of COVID-19 Remote Home Monitoring Services in England. PharmacoEconomics - open 8 (5) (2024)
Surachat Ngorsuraches, Tim C Lai, Rebecca Habermann, Yolanda Wheeler, William Meador
Using a Patient-Centered Multicriteria Decision Analysis to Assess the Value of Multiple Sclerosis Treatments in the US: A Study Protocol. PharmacoEconomics - open 8 (5) (2024)
She Hui Tan, Louise Gek Huang Goh, Benjamin Shao Kiat Ong, Darren Sze Guan Ng, Liang Lin, Raymond Chee Hui Ng, Bernard Yu-Hor Thong, Kwong Ng
Impact of Value-Driven Healthcare Strategies for Biosimilar Adoption: The Singapore Story. PharmacoEconomics - open 8 (5) (2024)
Paul Casabianca, Marc Massetti, François-Emery Cotte, Romain Moreau, Sarah Kassahun, Prianka Singh, Inkyu Kim, Anne-Françoise Gaudin, Guillaume Piessen, Henri Leleu
A Cost-Effectiveness Analysis of Adjuvant Nivolumab for Patients with Resected Esophageal Cancer or Gastroesophageal Junction Cancer in France. PharmacoEconomics - open 8 (5) (2024)
Andrew J Lloyd, Daniel Aggio, Caleb Dixon, Ernest H Law, Thomas Price
Psychometric Properties of the EQ-5D-5L in Patients with Alopecia Areata. PharmacoEconomics - open 8 (5) (2024)
Diana Beatriz S Bayani, Yihao Clement Lin, Chandramouli Nagarajan, Melissa Gaik-Ming Ooi, Allison Ching Yee Tso, John Cairns, Hwee Lin Wee
Modeling First-Line Daratumumab Use for Newly Diagnosed, Transplant-Ineligible, Multiple Myeloma: A Cost-Effectiveness and Risk Analysis for Healthcare Payers. PharmacoEconomics - open 8 (5) (2024)
Sonila M Tomini, Efthalia Massou, Nadia E Crellin, Naomi J Fulop, Theo Georghiou, Lauren Herlitz, Ian Litchfield, Pei Li Ng, Christopher Sherlaw-Johnson, Manbinder S Sidhu, Holly Walton, Stephen Morris
A Cost Evaluation of COVID-19 Remote Home Monitoring Services in England. PharmacoEconomics - open 8 (5) (2024)
Surachat Ngorsuraches, Tim C Lai, Rebecca Habermann, Yolanda Wheeler, William Meador
Using a Patient-Centered Multicriteria Decision Analysis to Assess the Value of Multiple Sclerosis Treatments in the US: A Study Protocol. PharmacoEconomics - open 8 (5) (2024)
Jonathan Salcedo, Daniel Hill-McManus, Chloë Hardern, Oyin Opeifa, Raffaella Viti, Ludovica Siviero, Antonio Saverio Roscini, Gennaro Di Martino
Cost-Effectiveness of Vedolizumab as a First-Line Advanced Therapy Versus Adalimumab Treatment Sequences for Ulcerative Colitis in Italy. PharmacoEconomics - open 8 (5) (2024)
Richard St John Nicholas, Erik Scalfaro, Rachel Dorsey, Zuzanna Angehrn, Judit Banhazi, Roisin Brennan, Nicholas Adlard
ENTIMOS: Decision Support Tool Highlights Potential Impact of Non-intravenous Therapies for Multiple Sclerosis on Patient Care via Clinical Scenario Simulation. PharmacoEconomics - open 8 (5) (2024)
Natalia Espinola, Constanza Silvestrini, Carla Colaci, Daniela Sugg, Carlos Rojas-Roque, Jesica Coelli, Federico Augustovski
Budget Impact Analysis of Olaparib for the Management of Patients with Homologous Recombination Repair (HRR)-Mutated Castration-Resistant Metastatic Prostate Cancer in Argentina. PharmacoEconomics - open 8 (5) (2024)
She Hui Tan, Louise Gek Huang Goh, Benjamin Shao Kiat Ong, Darren Sze Guan Ng, Liang Lin, Raymond Chee Hui Ng, Bernard Yu-Hor Thong, Kwong Ng
Impact of Value-Driven Healthcare Strategies for Biosimilar Adoption: The Singapore Story. PharmacoEconomics - open 8 (5) (2024)
Vittoria Ardito, Ludovico Cavallaro, Michael F Drummond, Oriana Ciani
Mapping Payment and Pricing Schemes for Health Innovation: Protocol of a Scoping Literature Review. PharmacoEconomics - open 8 (5) (2024)
Andrew J Lloyd, Daniel Aggio, Caleb Dixon, Ernest H Law, Thomas Price
Psychometric Properties of the EQ-5D-5L in Patients with Alopecia Areata. PharmacoEconomics - open 8 (5) (2024)
Jonathan Salcedo, Daniel Hill-McManus, Chloë Hardern, Oyin Opeifa, Raffaella Viti, Ludovica Siviero, Antonio Saverio Roscini, Gennaro Di Martino
Cost-Effectiveness of Vedolizumab as a First-Line Advanced Therapy Versus Adalimumab Treatment Sequences for Ulcerative Colitis in Italy. PharmacoEconomics - open 8 (5) (2024)
Natalia Espinola, Constanza Silvestrini, Carla Colaci, Daniela Sugg, Carlos Rojas-Roque, Jesica Coelli, Federico Augustovski
Budget Impact Analysis of Olaparib for the Management of Patients with Homologous Recombination Repair (HRR)-Mutated Castration-Resistant Metastatic Prostate Cancer in Argentina. PharmacoEconomics - open 8 (5) (2024)
Diana Beatriz S Bayani, Yihao Clement Lin, Chandramouli Nagarajan, Melissa Gaik-Ming Ooi, Allison Ching Yee Tso, John Cairns, Hwee Lin Wee
Modeling First-Line Daratumumab Use for Newly Diagnosed, Transplant-Ineligible, Multiple Myeloma: A Cost-Effectiveness and Risk Analysis for Healthcare Payers. PharmacoEconomics - open 8 (5) (2024)
Paul Casabianca, Marc Massetti, François-Emery Cotte, Romain Moreau, Sarah Kassahun, Prianka Singh, Inkyu Kim, Anne-Françoise Gaudin, Guillaume Piessen, Henri Leleu
A Cost-Effectiveness Analysis of Adjuvant Nivolumab for Patients with Resected Esophageal Cancer or Gastroesophageal Junction Cancer in France. PharmacoEconomics - open 8 (5) (2024)
Andrew J Lloyd, Daniel Aggio, Caleb Dixon, Ernest H Law, Thomas Price
Psychometric Properties of the EQ-5D-5L in Patients with Alopecia Areata. PharmacoEconomics - open 8 (5) (2024)
Natalia Espinola, Constanza Silvestrini, Carla Colaci, Daniela Sugg, Carlos Rojas-Roque, Jesica Coelli, Federico Augustovski
Budget Impact Analysis of Olaparib for the Management of Patients with Homologous Recombination Repair (HRR)-Mutated Castration-Resistant Metastatic Prostate Cancer in Argentina. PharmacoEconomics - open 8 (5) (2024)
Dawn Lee, Darren Burns, Ed Wilson
NICE's Pathways Pilot: Pursuing Good Decision Making in Difficult Circumstances. PharmacoEconomics - open 8 (5) (2024)
Surachat Ngorsuraches, Tim C Lai, Rebecca Habermann, Yolanda Wheeler, William Meador
Using a Patient-Centered Multicriteria Decision Analysis to Assess the Value of Multiple Sclerosis Treatments in the US: A Study Protocol. PharmacoEconomics - open 8 (5) (2024)
Paul Casabianca, Marc Massetti, François-Emery Cotte, Romain Moreau, Sarah Kassahun, Prianka Singh, Inkyu Kim, Anne-Françoise Gaudin, Guillaume Piessen, Henri Leleu
A Cost-Effectiveness Analysis of Adjuvant Nivolumab for Patients with Resected Esophageal Cancer or Gastroesophageal Junction Cancer in France. PharmacoEconomics - open 8 (5) (2024)